It has been described a high release of S100B in demyelinating disorders, and we have previously shown that in MS post-mortem active lesions, there is an elevated expression of S100B by astrocytes and of its receptor RAGE by macrophages/microglial cells (Barateiro et al., 2016). This evidence concerns the gene S100B and myeloid sarcoma.